AbbVie (ABBV) Wins EU Approval For Pediatric Skyrizi And Broader Maviret Use

• AbbVie (NYSE:ABBV) received European Commission approval for Skyrizi to treat children and adolescents with moderate to severe plaque psoriasis.
• The company also secured approval for Maviret as the only therapy authorized in the EU for both acute and chronic hepatitis C in patients as young as three.
• These back to back decisions broaden AbbVie’s reach in immunology and virology, particularly in pediatric and earlier stage treatment settings.

AbbVie is a large biopharmaceutical company with core franchises in immunology and virology, and these approvals relate directly to those businesses. The new Skyrizi label extension in pediatric psoriasis and the broader Maviret authorization in hepatitis C bring fresh attention to products that sit alongside AbbVie’s more widely discussed immunology and neuro portfolios. For investors, the news illustrates how regulatory decisions can reshape the mix of potential revenue drivers without relying on entirely new product launches.

These approvals may influence how you think about AbbVie’s mix of opportunities, particularly its exposure to earlier intervention and high-need patient groups. The expanded labels enlarge the potential treated population and could affect how payers, clinicians and competitors position therapies in both psoriasis and hepatitis C over time, adding new angles to the investment debate around NYSE:ABBV.

Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.

📰 Beyond the headline: 4 risks and 2 things going right for AbbVie that every investor should see.

Quick Assessment

• ⚖️ Price vs Analyst Target: AbbVie trades at US$243.14 versus an average analyst target of US$254.38, about 5% below consensus.
• ✅ Simply Wall St Valuation: The stock is flagged as trading roughly 44% below an estimated fair value, suggesting a sizable valuation gap.
• ✅ Recent Momentum: A 30 day return of 14.1% shows strong recent share price momentum around these European approvals.

There's only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's company report for the latest analysis of AbbVie's Fair Value.

Key Considerations

• 📊 The dual European approvals expand AbbVie’s reach in pediatric immunology and hepatitis C, which can affect how durable its broader portfolio is viewed.
• 📊 Watch prescription trends for Skyrizi and Maviret in younger patients, as well as any commentary from management on uptake in early stage treatment settings.
• ⚠️ AbbVie still carries high debt and negative shareholders’ equity, so investors may want to weigh new label opportunities against balance sheet and dividend coverage risks.

Dig Deeper

For the full picture including more risks and rewards, check out the complete AbbVie analysis. Alternatively, you can check out the community page for AbbVie to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com